Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine


Ganesh S.  Palapattu, M.D., F.A.C.S.

Ganesh S. Palapattu, M.D., F.A.C.S.

Associate Member
Houston Methodist Research Institute
Chief of Urologic Oncology
Department of Urology
Houston Methodist Hospital

Phone: 713-441-8138
Fax: 713-441-6463
E-mail: gpalapattu@houstonmethodist.org


B.A.   The University of Texas at Austin, Austin, TX (Humanities)
M.D.   Baylor College of Medicine, Houston, TX

Postdoctoral Training

Surgical Internship, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Urology Residency, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Urologic Oncology Fellowship, Johns Hopkins University School of Medicine, Baltimore, MD



After completing his postdoctoral training, Dr. Palapattu joined the faculty at the University of Rochester School of Medicine as an Assistant Professor in the Department of Urology. While there, he also co-directed the urology residency program. In 2007, he received two additional faculty appointments at the university; as Assistant Professor in the Departments of Pathology and Laboratory Medicine, and Oncology. Dr. Palapattu joined Houston Methodist Hospital and Research Institute in 2009.

Description of Research

As a surgeon-scientist, Dr. Palapattu’s research focus is centered on uncovering the mechanisms behind the pathogenesis of advanced prostate cancer. His laboratory is currently investigating the role of cancer stem cells in prostate cancer recurrence.

Major Areas of Research

Prostate cancer, stem cells, biomarkers, radical prostatectomy, metastasis.

Recent Publications

Mener DJ, Cambio A, Stoddard DG, Martin BA, Palapattu GS. The impact of HMG-CoA reductase therapy on serum PSA. Prostate. 2009 Dec 8. [Epub ahead of print]

Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug;182(2):459-65.

Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate. 2009 May 15;69(7):787-98.

Capitanio U, Suardi N, Shariat SF, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May;103(10):1359-62.

Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009 Feb;40(2):252-8.